According to the chief ministers’ guidelines, the provincial departments are required to complete the approval process for new projects by March 31, 2025, to ensure timely inclusion in the ADP.

ADPA-2AFP is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Pancreatic Cancer.

Poly-(ADP-ribose) polymerase inhibitors in clinical ... Repair of these DSBs requires homologous recombinaion (HR) for efficient repair, a process which is defective in hereditary breast cancer ...